Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
Feature|Articles|September 18, 2026
Vitamin K Refusals Are Rising: What Payers Need to Know
Author(s)Sabrina McCrear
Fact checked by: Laura Joszt, MA, William Schaffner, MD
Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.
Advertisement
Advertisement
Vitamin K shot refusals among newborns in the US have risen 77%, from 2.92% in 2017 to 5.18% in 2024, leading clinicians interviewed for this piece to believe broader
Related to this article
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Panelists ask whether cancer care will shift toward home-administered infusions as payers push for change. Other topics in this forward-looking session include new delivery tech and practice-led solutions.
Advertisement
Advertisement